Clinical Trial News and Research

RSS

FORT-2 trial shows promising results for bladder cancer immunotherapy combination

Findings from the international FORT-2 clinical trial showed that a combination treatment including immunotherapy is safe and tolerable in patients with locally advanced or metastatic bladder cancer.

19 Sep 2024

Adaptive platform trial tests multiple treatments for traumatic brain injury

Traumatic brain injury (TBI) results in close to 70,000 deaths in the United States every year, and it is the cause of long-term physical, cognitive and mental disability in 5 million Americans. But despite three decades of work, treatments are sorely lacking.

19 Sep 2024

Drug breakthrough provides new hope for cancer patients with cachexia

Researchers discovered a drug that safely and effectively helped cancer patients when they suffered from cachexia (ku-KEK-see-uh), a common condition related to cancer that involves weight loss and muscle wasting.

19 Sep 2024

Study reveals impact of human breast milk on infant microbiome and respiratory health

Human breast milk regulates a baby's mix of microbes, or microbiome, during the infant's first year of life. This in turn lowers the child's risk of developing asthma, a new study shows.

19 Sep 2024

Liposomal bupivacaine shows no advantage in postoperative pain management for older adults

For older adults undergoing hemiarthroplasty for hip fracture, intraoperative use of liposomal bupivacaine does not improve pain scores or other relevant outcomes, compared to conventional bupivacaine, reports a study in The Journal of Bone & Joint Surgery.

19 Sep 2024

New biopsy technique reduces infection risk in prostate cancer detection

A multi-institutional clinical trial led by Weill Cornell Medicine and NewYork-Presbyterian investigators showed that a newer technique for collecting prostate biopsy samples reduced the risk of infection compared with traditional biopsy approaches.

19 Sep 2024

Phase 1 trial shows safety and efficacy of personalized vaccine for lymphoplasmacytic lymphoma

A team of researchers from City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the U.S., and The University of Texas M.D. Anderson Cancer Center, have reported safety and efficacy results from a Phase 1 trial that featured a personalized vaccine to treat lymphoplasmacytic lymphoma, a rare and slow-growing type of blood cancer, according to a study published recently in Nature Communications.

19 Sep 2024

Multiple myeloma drug shows efficacy in treating rare bleeding disorder

A drug approved for treating the blood cancer multiple myeloma may offer a safe and effective way to reduce the risk of severe nosebleeds from a rare but devastating bleeding disorder.

19 Sep 2024

Clinical trial demonstrates effectiveness of drip iron for anemia

Researchers found that a medicine called ferric carboxymaltose given in drip through the vein works faster and better than an iron tablet taken by mouth for the treatment of anemia – and it is as safe as the tablet. The findings were published in Lancet Global Health.

19 Sep 2024

Cancer drug shows promise for treating rare bleeding disorder

A clinical trial has demonstrated that the cancer drug pomalidomide is safe and effective in treating hereditary hemorrhagic telangiectasia (HHT), a rare bleeding disorder that impacts more than 1 in 5,000 people worldwide. The trial, led by Keith McCrae, M.D., of Cleveland Clinic and supported by the National Institutes of Health, was stopped early because of these successful findings, and has been published in the New England Journal of Medicine.

19 Sep 2024

Early intervention key for mental health in children with cystic fibrosis

A University at Buffalo psychiatrist who has played a critical role in getting mental health screening and treatment integrated into routine care for adults and adolescents with cystic fibrosis (CF) has been awarded $3 million from the Cystic Fibrosis Foundation to focus on the mental health of children with the disease.

19 Sep 2024

New biomarkers offer hope for early detection and prevention of Alzheimer's

The failure to diagnose Alzheimer's disease, the most common form of dementia in the elderly, at an early stage of molecular pathology is considered a major reason why treatments fail in clinical trials. Previous research to molecularly diagnose Alzheimer's disease yielded "A/T/N" central biomarkers based on the measurements of proteins, β-amyloid ("A") and tau ("T"), and "N" encompassing neurodegeneration. A/T/N can be measured in brain tissue, by in vivo brain imaging techniques, and by analysis of cerebrospinal fluid and plasma.

18 Sep 2024

Clinical trial finds pomalidomide effective for treating rare bleeding disorder

A clinical trial supported by the National Institutes of Health (NIH) was stopped early after researchers found sufficient evidence that a drug used to treat bone marrow cancer and Kaposi sarcoma is safe and effective in treating hereditary hemorrhagic telangiectasia (HHT), a rare bleeding disorder that affects 1 in 5,000 people worldwide.

18 Sep 2024

Speech analysis phone app could identify early signs of hepatic encephalopathy

Research from the University of Michigan suggests that one day a phone app could be able to detect the development of hepatic encephalopathy in patients just by listening to them speak.

18 Sep 2024

Casual blood glucose test misses majority of gestational diabetes cases

When screening pregnant women for gestational diabetes, casual blood glucose testing misses 70% of the cases.

18 Sep 2024

NIH-funded study compares eyelid surgeries for Trachomatous trichiasis

Trachomatous trichiasis, a potentially blinding condition where inward-turned eyelashes scratch the front of the eye, can successfully be treated by either of the two most common types of eyelid surgery, according to findings from a large comparison trial funded by the National Institutes of Health.

18 Sep 2024

Innovative triplet therapy shows encouraging results in advanced chronic myeloid leukemia

According to researchers at The University of Texas MD Anderson Cancer Center, 80% of patients with previously untreated or relapsed/refractory advanced-phase chronic myeloid leukemia (CML) – including both accelerated or myeloid blast phases of the disease – or Philadelphia chromosome-positive acute myeloid leukemia (AML) achieved a bone marrow remission when treated with a novel combination of decitabine, venetoclax and ponatinib.

17 Sep 2024